Palvella gets FDA priority review for lead asset (PVLA:NASDAQ)
· seekingalpha.com
Palvella Therapeutics (PVLA) stock rose after the company won the FDA priority review for its marketing application for its lead asset, Qtorin rapamycin. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...